USP12 downregulation orchestrates a protumourigenic microenvironment and enhances lung tumour resistance to PD-1 blockade.

USP12 downregulation orchestrates a protumourigenic microenvironment and enhances lung tumour resistance to PD-1 blockade.
复制标题

USP12 下调协调促肿瘤微环境并增强肺部肿瘤对 PD-1 阻断的抵抗力

DOI:
10.1038/s41467-021-25032-5
复制
发表时间:
2021-08-11
影响因子:
16.6
通讯作者:
Liu Y
Liu Y
中科院分区:
综合性期刊1区
文献类型:
--
作者:
Yang Z;Xu G;Wang B;Liu Y;Zhang L;Jing T;Tang M;Xu X;Jiao K;Xiang L;Fu Y;Tang D;Zhang X;Jin W;Zhuang G;Zhao X;Liu Y

文献摘要

参考文献

被引文献

相似文献

KRAS及其替代物的致癌激活对于肿瘤细胞的增殖和生存以及促癌微环境的发展是必不可少的。在这里,我们发现去泛素酶USP12在KrasG12D驱动的小鼠肺癌和人类非小细胞肺癌中通常下调,这是由于AKT-mTOR信号的激活。USP12的下调促进了肺癌的生长,并促进了免疫抑制的微环境,增加了巨噬细胞的募集,增加了血管生成,减少了T细胞的激活。从机制上讲,由于PPM1B去泛素化不足,导致肿瘤细胞中的NF-κB过度激活,USP12的下调产生了促进肿瘤的分泌体。此外,抑制USP12使小鼠肺肿瘤细胞对抗PD-1免疫治疗不敏感。因此,我们的发现提出了在肿瘤-免疫细胞相互作用和肿瘤对免疫检查点阻断治疗的反应的调节中,致癌信号通路下游的关键组成部分。
Oncogenic activation of KRAS and its surrogates is essential for tumour cell proliferation and survival, as well as for the development of protumourigenic microenvironments. Here, we show that the deubiquitinase USP12 is commonly downregulated in theKrasG12D-driven mouse lung tumour and human non-small cell lung cancer owing to the activation of AKT-mTOR signalling. Downregulation of USP12 promotes lung tumour growth and fosters an immunosuppressive microenvironment with increased macrophage recruitment, hypervascularization, and reduced T cell activation. Mechanistically, USP12 downregulation creates a tumour-promoting secretome resulting from insufficient PPM1B deubiquitination that causes NF-κB hyperactivation in tumour cells. Furthermore, USP12 inhibition desensitizes mouse lung tumour cells to anti-PD-1 immunotherapy. Thus, our findings propose a critical component downstream of the oncogenic signalling pathways in the modulation of tumour-immune cell interactions and tumour response to immune checkpoint blockade therapy.
DOI: 10.1038/s41467-018-05653-z
发表时间: 2018-09-28
影响因子: 16.6
作者:
Aron R;Pellegrini P;Green EW;Maddison DC;Opoku-Nsiah K;Oliveira AO;Wong JS;Daub AC;Giorgini F;Muchowski P;Finkbeiner S
通讯作者: Finkbeiner S
DOI: 10.1002/ijc.24748
发表时间: 2009-12-15
影响因子: 6.4
作者:
Bai, Dong;Ueno, Lynn;Vogt, Peter K.
通讯作者: Vogt, Peter K.
DOI: 10.1126/science.1194472
发表时间: 2010-12-03
期刊: Science (New York, N.Y.)
影响因子: --
作者:
Harbour JW;Onken MD;Roberson ED;Duan S;Cao L;Worley LA;Council ML;Matatall KA;Helms C;Bowcock AM
通讯作者: Bowcock AM
DOI: 10.1038/nrd.2017.152
发表时间: 2018-01
期刊: Nature reviews. Drug discovery
影响因子: --
作者:
Harrigan JA;Jacq X;Martin NM;Jackson SP
通讯作者: Jackson SP
DOI: 10.1093/nar/gkv1507
发表时间: 2016-05-05
影响因子: 14.9
作者:
Colaprico A;Silva TC;Olsen C;Garofano L;Cava C;Garolini D;Sabedot TS;Malta TM;Pagnotta SM;Castiglioni I;Ceccarelli M;Bontempi G;Noushmehr H
通讯作者: Noushmehr H